Antitumor activity of recombinant oncolytic vaccinia virus with human IL2

Area of Science:

• Oncolytic virotherapy
• Cancer immunotherapy
• Molecular virology

Background:

• The tumor microenvironment often suppresses anti-cancer immune responses.
• Genetically modified oncolytic vaccinia virus (OVV) presents a promising strategy for cancer immunotherapy.
• Enhancing OVV with immune-stimulating cytokines may improve therapeutic efficacy.

Purpose of the Study:

• To evaluate the in vitro antitumor effects of a recombinant OVV engineered to express human interleukin-2 (hIL2).
• To assess the impact of hIL2 gene insertion on viral replication and lytic activity.

Main Methods:

• A double-deleted OVV (VVDD) was engineered to express hIL2, creating rVVDD-hIL2.
• Viral replication was quantified using plaque titration assays.
• hIL2 production was measured via ELISA.
• Antitumor effects were assessed using the MTS assay.

Main Results:

• rVVDD-hIL2 demonstrated dose-dependent expression of hIL2 in infected cancer cells.
• hIL2 gene insertion did not compromise the viral replication capacity of VVDD.
• The recombinant virus effectively lysed tumor cells, with lytic activity increasing at higher multiplicities of infection (MOIs).

Conclusions:

• hIL2-armed VVDD exhibits significant potential as an oncolytic virus therapy.
• The engineered virus efficiently infects and lyses tumor cells while expressing therapeutic levels of hIL2.
• This approach offers a promising strategy for overcoming tumor immunosuppression in cancer treatment.